edoc

Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia

Szucs, T. D. and Blank, P. R. and Schwenkglenks, M. and Aapro, M.. (2011) Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology, 81 (1). pp. 45-49.

[img]
Preview
PDF - Published Version
96Kb

Official URL: http://edoc.unibas.ch/dok/A6004745

Downloads: Statistics Overview

Abstract

Intravenous (i.v.) iron supplementation significantly improves the response to erythropoiesis-stimulating agent (ESA)-based therapies in patients with cancer- or chemotherapy-induced anemia. The economic implications of adding i.v. iron to ESA treatment are less well investigated. Published randomized controlled trials do not provide sufficient data for a comprehensive cost-effectiveness analysis.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Pharmazeutische Medizin ECPM > Pharmazeutische Medizin (Szucs)
UniBasel Contributors:Schwenkglenks, Matthias and Blank, Patricia R.
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Karger
ISSN:0030-2414
e-ISSN:1423-0232
Note:Publication type according to Uni Basel Research Database: Journal article
Language:English
Identification Number:
edoc DOI:
Last Modified:25 Oct 2017 07:03
Deposited On:13 Sep 2013 07:48

Repository Staff Only: item control page